Nutrien Past Earnings Performance
Past criteria checks 1/6
Nutrien has been growing earnings at an average annual rate of 45.3%, while the Chemicals industry saw earnings declining at 2.5% annually. Revenues have been growing at an average rate of 14.5% per year. Nutrien's return on equity is 5.1%, and it has net margins of 4.5%.
Key information
45.3%
Earnings growth rate
46.9%
EPS growth rate
| Chemicals Industry Growth | 4.3% |
| Revenue growth rate | 14.5% |
| Return on equity | 5.1% |
| Net Margin | 4.5% |
| Next Earnings Update | 08 May 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Nutrien makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 28,082 | 1,258 | 4,014 | 0 |
| 30 Sep 23 | 29,967 | 2,198 | 3,949 | 0 |
| 30 Jun 23 | 32,583 | 3,700 | 3,959 | 0 |
| 31 Mar 23 | 35,466 | 6,853 | 3,992 | 0 |
| 31 Dec 22 | 37,012 | 7,660 | 4,050 | 0 |
| 30 Sep 22 | 36,792 | 7,749 | 4,180 | 0 |
| 30 Jun 22 | 34,612 | 6,889 | 4,101 | 0 |
| 31 Mar 22 | 29,868 | 4,404 | 4,015 | 0 |
| 31 Dec 21 | 26,861 | 3,153 | 3,826 | 0 |
| 30 Sep 21 | 23,642 | 2,268 | 3,663 | 0 |
| 30 Jun 21 | 21,861 | 964 | 3,552 | 0 |
| 31 Mar 21 | 20,514 | 621 | 3,409 | 0 |
| 31 Dec 20 | 20,053 | 459 | 3,324 | 0 |
| 30 Sep 20 | 19,534 | 95 | 3,213 | 0 |
| 30 Jun 20 | 19,470 | 823 | 3,084 | 0 |
| 31 Mar 20 | 19,754 | 916 | 3,052 | 0 |
| 31 Dec 19 | 19,316 | 992 | 3,028 | 0 |
| 30 Sep 19 | 19,671 | 1,336 | 2,889 | 0 |
| 30 Jun 19 | 19,449 | 128 | 2,929 | 0 |
| 31 Mar 19 | 18,862 | 11 | 2,930 | 0 |
| 31 Dec 18 | 18,772 | -31 | 2,891 | 0 |
| 30 Sep 18 | 16,051 | -447 | 2,298 | 0 |
| 30 Jun 18 | 13,376 | 636 | 1,631 | 0 |
| 31 Mar 18 | 6,489 | 47 | 829 | 0 |
| 31 Dec 17 | 4,010 | 154 | 233 | 0 |
| 30 Sep 17 | 3,973 | 196 | 218 | 0 |
| 30 Jun 17 | 3,893 | 261 | 221 | 0 |
| 31 Mar 17 | 3,824 | 230 | 233 | 0 |
| 31 Dec 16 | 3,921 | 199 | 231 | 0 |
| 30 Sep 16 | 4,239 | 478 | 253 | 0 |
| 30 Jun 16 | 4,658 | 679 | 246 | 0 |
| 31 Mar 16 | 5,330 | 975 | 251 | 0 |
| 31 Dec 15 | 5,791 | 1,115 | 258 | 0 |
| 30 Sep 15 | 6,303 | 1,476 | 258 | 0 |
| 30 Jun 15 | 6,402 | 1,511 | 255 | 0 |
| 31 Mar 15 | 6,529 | 1,566 | 250 | 0 |
| 31 Dec 14 | 6,506 | 1,536 | 258 | 0 |
| 30 Sep 14 | 6,152 | 1,359 | 255 | 0 |
| 30 Jun 14 | 6,033 | 1,398 | 254 | 0 |
| 31 Mar 14 | 6,296 | 1,569 | 250 | 0 |
| 31 Dec 13 | 6,733 | 1,785 | 248 | 0 |
| 30 Sep 13 | 6,858 | 1,976 | 218 | 0 |
| 30 Jun 13 | 7,466 | 2,265 | 223 | 0 |
Quality Earnings: 0NHS has a large one-off loss of $823.0M impacting its last 12 months of financial results to 31st December, 2023.
Growing Profit Margin: 0NHS's current net profit margins (4.5%) are lower than last year (20.7%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 0NHS has become profitable over the past 5 years, growing earnings by 45.3% per year.
Accelerating Growth: 0NHS's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 0NHS had negative earnings growth (-83.6%) over the past year, making it difficult to compare to the Chemicals industry average (-18.4%).
Return on Equity
High ROE: 0NHS's Return on Equity (5.1%) is considered low.